BridgeBio Pharma Inc

BridgeBio Pharma Inc

BBIO

Get informed when a big investor buys or sells

+ Follow
Market Cap$15B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
BridgeBio Pharma IncBridgeBio Pharma Inc-21.4-28%25.1-1
$108.38

Target Price by Analysts

43.7% upsideBridgeBio Pharma Target Price DetailsTarget Price
$-76.74

Current Fair Value

201.8% downside

Overvalued by 201.8% based on the discounted cash flow analysis.

Share Statistics

Market cap$15.00 Billion
Enterprise Value$16.82 Billion
Dividend Yield$- (-)
Earnings per Share$-3.79
Beta0.98
Outstanding Shares195,785,884

Return

Return on Equity27.68%ROE
Return on Assets-57.20%
Return on Invested Capital-186.30%

Valuation & Multiples

P/E Ratio-21.4P/E Ratio
PEG131.11PEG
Price to Sales25.14Price to Sales
Price to Book Ratio-5.8Price to Book Ratio
Enterprise Value to Revenue24.82
Enterprise Value to EBIT-27.65
Enterprise Value to Net Income-25
Total Debt to Enterprise0.15
Debt to Equity-0.99Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
August 10, 2026
EPS Estimate
$-0.58
Average shareholder expectation
Revenue Estimate
$220.91 M
Average shareholder expectation

Next Earnings Call

Expected Date
October 28, 2026
EPS Estimate
$-0.61
Average shareholder expectation
Revenue Estimate
$270.33 M
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio0.1652▲ 1.48%
Total Calls11,050,000▲ 6.51%
Total Puts1,825,800▲ 17.02%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %106.64%▲ 6.72%
Total Invested$14.70B▲ 1.94%
Investors Holding511▲ 18.00%

ESG Score

No data

About BridgeBio Pharma Inc

CEO: Neil Kumar